Capital is flocking to a few high-growth AI plays and ignoring other opportunities because of the AI trend in the markets. The fear of a patent cliff (loss of revenue from a drug going off-patent) for …
Novartis: A Mispriced Hedge In A Crowded Equity Market
view original post